Why the study?
Metabolic syndrome-mediated HFpEF is commonly accompanied by left atrial cardiomyopathy, but the role of reactive oxygen species and intrinsic inflammation related to dysfunctional Ca2+ homeostasis in LA cardiomyocytes remains unclear.
Does inflammatory modulation with TNF-α or IL-10 affect Ca2+ homeostasis in left atrial cardiomyocytes in a rat model of metabolic HFpEF?
Does inflammatory modulation with TNF-α or IL-10 affect Ca2+ homeostasis in left atrial cardiomyocytes in a rat model of metabolic HFpEF?
Anti-inflammatory treatment with IL-10 improves dysfunctional Ca2+ homeostasis in a rat model of metabolic HFpEF-related left atrial cardiomyopathy, suggesting a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
May implicate ROS in metabolic HFpEF atrial cardiomyopathy; hypothesis-generating and should not change practice.
Metabolic syndrome-mediated heart failure with preserved ejection fraction (HFpEF) is commonly accompanied by left atrial (LA) cardiomyopathy, significantly affecting morbidity and mortality. We evaluate the role of reactive oxygen species (ROS) and intrinsic inflammation (TNF-α, IL-10) related to dysfunctional Ca2+ homeostasis of LA cardiomyocytes in a rat model of metabolic HFpEF. ZFS-1 obese rats showed features of HFpEF and atrial cardiomyopathy in vivo: increased left ventricular (LV) mass, E/e’ and LA size and preserved LV ejection fraction. In vitro, LA cardiomyocytes exhibited more mitochondrial-fission (MitoTracker) and ROS-production (H2DCF). In wildtype (WT), pro-inflammatory TNF-α impaired cellular Ca2+ homeostasis, while anti-inflammatory IL-10 had no notable effect (confocal microscopy; Fluo-4). In HFpEF, TNF-α had no effect on Ca2+ homeostasis associated with decreased TNF-α receptor expression (western blot). In addition, IL-10 substantially improved Ca2+ release and reuptake, while IL-10 receptor-1 expression was unaltered. Oxidative stress in metabolic syndrome mediated LA cardiomyopathy was increased and anti-inflammatory treatment positively affected dysfunctional Ca2+ homeostasis. Our data indicates, that patients with HFpEF-related LA dysfunction might profit from IL-10 targeted therapy, which should be further explored in preclinical trials.
No takes yet. Share an insight, caveat, or question.
Bode et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: